Jim Cramer on CoreWeave: 'You Gotta Do Some Selling Here'
CoreWeave, Inc. (NASDAQ:CRWV) is one of the 14 stocks Jim Cramer recently shared insights on. Highlighting the short selling in the stock, Cramer commented:
'Take CoreWeave. This is the company that came public at $40 a share, [a] company I recommended and pushed incredibly hard to. People didn't believe me. Many chose to bet against the stock. 32% of the shares are sold short. On Friday, CoreWeave hit a high of $187. Stock still sits at $172 and change. Sure, it reported a great quarter, but a lot of this move is because so many people were betting against it because the company picked a bad time to come public.
A trader in an office, surrounded by financial charts and graphs, looking intently at a stock ticker.
CoreWeave (NASDAQ:CRWV) delivers a cloud platform focused on accelerating and scaling compute-intensive workloads, especially for generative AI. The company provides high-performance computing resources, infrastructure management, and services for AI training, inference, rendering, and dataset optimization.
While we acknowledge the potential of CRWV as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Erreur lors de la récupération des données
Connectez-vous pour accéder à votre portefeuille
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Erreur lors de la récupération des données
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
4 minutes ago
- Associated Press
AOFAR Officially Launches GX6: The Top Budget Rechargeable Golf Rangefinder for 2025
NEW YORK, June 28, 2025 /CNW/ -- AOFAR today announced the release of the GX6 Golf Rangefinder, a leading choice for golfers seeking the best rechargeable golf rangefinder. The GX6 offers slope-adjusted distance, ultra-fast 0.02-second flag lock, a powerful magnetic cart mount, and modern USB-C rechargeable power, bringing high-end features to budget-conscious players. Weighing only 162g, the GX6 is one of the lightest golf rangefinders in its class, providing a comfortable and intuitive experience on the course. Its advanced optics deliver crisp visuals at 7× magnification with slope mode that can be toggled for tournament play. The built-in N52-grade magnetic mount allows golfers to securely attach the device to carts or clubs for fast, convenient access. The GX6's USB-C rechargeable battery delivers up to 12,000 distance measurements on a single charge, offering superior convenience and cost-efficiency compared to traditional battery-powered rangefinders. It's a 0.02-second flag lock with vibration feedback that ensures quick, accurate yardages, a must-have for faster-paced rounds. 'The GX6 delivers exceptional value for golfers looking to upgrade their gear in 2025,' said an AOFAR CEO, Mr Ding. 'It combines speed, lightweight design, rechargeable convenience, and tournament-ready accuracy — all for under $70. It's ideal for casual golfers, beginners, or anyone moving up from older battery-powered models.' Priced at just $69, the AOFAR GX6 Rechargeable Golf Rangefinder is now available on Amazon US and About AOFAR AOFAR is a global brand specializing in laser rangefinders and precision optics. From golfers to hunters and outdoor explorers, AOFAR delivers pro-grade performance at an accessible price. Learn more at Media Contact: Marketing director: Kris Ding Email: [email protected] View original content to download multimedia: SOURCE AOFAR
Associated Press
4 minutes ago
- Associated Press
Rocket Lab Completes Record Launch Turnaround From Launch Complex 1, Successfully Deploys 68th Electron Mission
MAHIA, New Zealand--(BUSINESS WIRE)--Jun 28, 2025-- Rocket Lab Corporation (Nasdaq: RKLB) ('Rocket Lab' or 'the Company'), a global leader in launch services and space systems, today successfully launched its 68th Electron rocket to deploy a single satellite to space for a confidential commercial customer. The mission was the second of two launches from the same launch site in less than 48 hours, a new launch record for the Company as it continues to deliver dedicated, repeatable and reliable access to space for satellite operators. The 'Symphony In The Stars' mission lifted-off from Rocket Lab Launch Complex 1 in Mahia, New Zealand on June 28 th (7:08 p.m./07:08 UTC) to deploy a single spacecraft to a 650km circular Earth orbit. The mission was the first of two dedicated launches for the new customer on Electron booked less than four months ago, with a second mission scheduled before the end of 2025. Rocket Lab has now completed four launches in June for commercial satellite constellation operators, underscoring Electron's consistent performance and rapid deployment capabilities as the world's leading small launcher: the 'Full Stream Ahead' mission on June 3 rd; 'The Mountain God Guards' mission on June 11 th; 'Get The Hawk Outta Here' launched on June 26 th UTC, and today's 'Symphony In The Stars' mission. Rocket Lab Founder and CEO, Sir Peter Beck, says: 'Electron has demonstrated once again that it is the gold standard for responsive and reliable space access for small satellites. The future of space is built on proven performance, and Electron continues to deliver against a stacked launch manifest this year. Congratulations to the team on achieving its fastest launch turnaround yet between two missions from Launch Complex 1. This launch was also a quick-turn mission to meet our customer's mission requirements, and we're looking forward to doing it again later this year.' 'Symphony In The Stars' was Rocket Lab's tenth Electron mission of 2025 and its 68th launch overall. With 100% mission success so far this year, Electron continues to deliver reliable deployment amid an increasing launch cadence and rapid contract-to-launch timelines. Launch images: Launch webcast: View source version on CONTACT: Rocket Lab Media Contact Murielle Baker [email protected] KEYWORD: AUSTRALIA/OCEANIA NEW ZEALAND INDUSTRY KEYWORD: TECHNOLOGY AEROSPACE MANUFACTURING SATELLITE SOURCE: Rocket Lab Corporation Copyright Business Wire 2025. PUB: 06/28/2025 04:45 AM/DISC: 06/28/2025 04:45 AM
Associated Press
4 minutes ago
- Associated Press
Lead Plaintiff Deadline is July 14, 2025 for Investors of Iovance Biotherapeutics, Inc. (IOVA)
NEW YORK, NY - June 28, 2025 ( NEWMEDIAWIRE ) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Iovance Biotherapeutics, Inc. ('Iovance' or the 'Company') (NASDAQ: IOVA) on behalf of investors that purchased or otherwise acquired Iovance securities between May 9, 2024 and May 8, 2025 (the 'Class Period'). CLICK HERE TO JOIN THE CASE If you are an investor in Iovance and have suffered losses, you may CLICK HERE to contact us. You may also contact Kaplan Fox by emailing [email protected] or by calling (212) 329-8571. DEADLINE REMINDER: If you are a member of the proposed Class, you may move the court no later than July 14, 2025 to serve as a lead plaintiff for the purported class. If you have losses we encourage you to contact us to learn more about the lead plaintiff process. You need not seek to become a lead plaintiff in order to share in any possible recovery. On May 8, 2025, after the markets closed, Iovance announced its first quarter 2025 financial results. The Company revealed that total product revenue for the quarter was $49.3 million, a decline from the prior quarter's reported revenue of $73.7 million. The Company also disclosed that full fiscal year 2025 revenue guidance was being revised to $250 million to $300 million from previous guidance of $450 million to $475 million. Iovance stated that it was 'revising full-year 2025 revenue guidance to reflect recent launch dynamics' of the Company's T cell immunotherapy, Amtagvi (lifileucel). Amtagvi was approved by the U.S. Food and Drug Administration in February 2024 and was commercially launched in the first half of 2024. Following this news, the price of Iovance stock fell $1.42 per share, nearly 45%, to close at $1.75 per share on May 9, 2025. The complaint alleges, among other things, that throughout the Class Period, Defendants made false and/or misleading statements and/or failed to disclose that Defendants, (i) new Authorized Treatment Centers were experiencing longer timelines to begin treating patients with Amtagvi; (ii) the Company's sales team and new ATCs were ineffective in patient identification and patient selection for Amtagvi, leading to higher patient drop-offs; and (iii) the foregoing dynamics led to higher costs and lower revenue because ATCs could not keep pace with manufactured product. WHY CONTACT KAPLAN FOX - Kaplan Fox is a leading national law firm focusing on complex litigation with offices in New York, Oakland, Los Angeles, Chicago and New Jersey. With over 50 years of experience in securities litigation, Kaplan Fox offers the professional experience and track record that clients demand. Through prosecuting cases on the federal and state levels, Kaplan Fox has successfully shaped the law through winning many important decisions on behalf of our clients. For more information about Kaplan Fox & Kilsheimer LLP, you may visit our website at This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules. If you have any questions about this Notice, your rights, or your interests, please contact: CONTACT: Jeffrey P. Campisi KAPLAN FOX & KILSHEIMER LLP 800 Third Avenue, 38th Floor New York, New York 10022 (212) 329-8571 [email protected] Laurence D. King KAPLAN FOX & KILSHEIMER LLP 1999 Harrison Street, Suite 1560 Oakland, California 94612 (415) 772-4704 [email protected] Contacting or submitting information to Kaplan Fox & Kilsheimer LLP does not create an attorney-client relationship, nor an obligation on the part of Kaplan Fox to retain you as a client.
